Antivirals in the treatment of adult t cell leukaemia-lymphoma(ATLL)

Current Hematologic Malignancy Reports

Volumn 7, Issue 4, 2012, Pages 267-275

  Fields, Paul A ^a   Taylor, Graham P ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Adult Tcell Leukaemia Lymphoma (ATLL); Antiviral Therapy (AVT)

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; HISTONE DEACETYLASE INHIBITOR; LAMIVUDINE; MITOXANTRONE; PREDNISONE; RANIMUSTINE; TENOFOVIR; VINCRISTINE; VINDESINE; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG EFFICACY; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; OVERALL SURVIVAL; T CELL LEUKEMIA; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL;

EID: 84872178803     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-012-0139-9     Document Type: Article

References (49)

1. Mier JW, Gallo RC. Purification and some characteristics of human T-cell growth factor from phytohemagglutinin-stimulated lymphocyte-conditioned media. Proc Natl Acad Sci USA. 1980;77(10):6134-8. (Pubitemid 11206356)
2. Poiesz BJ, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA. 1980;77 (12):7415-9. (Pubitemid 11131140)
3. Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA. 1982;79 (6):2031-5. (Pubitemid 12088563)
4. IARC Monographs on the Evaluation of Carcinogenic Risk to Humans. Human immunodeficiency viruses and human T cell lymphotropic viruses. Lyon: IARC; 1996.
5. Murphy EL, et al. Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. Int J Cancer. 1989;43(2):250-3. (Pubitemid 19062419)
6. Bazarbachi A, et al. New therapeutic approaches for adult T-cell leukaemia. Lancet Oncol. 2004;5(11):664-72.
7. Kondo T, et al. Age-And sex-specific cumulative rate and risk of ATLL for HTLV-I carriers. Int J Cancer. 1989;43(6):1061-4. (Pubitemid 19158038)
8. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79 (3):428-37. Original description of ATLL into disease subtypes.
9. Amano M, et al. New entity, definition and diagnostic criteria of cutaneous adult T-cell leukemia/lymphoma: human T-lymphotropic virus type 1 proviral DNA load can distinguish between cutaneous and smoldering types. J Dermatol. 2008;35(5):270-5. (Pubitemid 351678093)
10. Okayama A. Natural history of human T-lymphotropic virus type 1 (HTLV-1) infection. Rinsho Byori. 2005;53(9):837-44.
11. Iwanaga M, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood. 2010;116 (8):1211-9.
12. Hodson et al. Pre Morbid Human T Lymphotropic virus type I proviral load, rather than percentage of abnormal lymphmocytes, is associated with an increased risk of Agressive T cell Leukamia/Lymphoma. In press Haematolgica; 2012.
13. Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer. 2007;7(4):270-80.
14. Afonso PV, et al. Centrosome and retroviruses: the dangerous liaisons. Retrovirology. 2007;4:27.
15. Mariner JM, et al. Human T cell lymphotropic virus type I Tax activates IL-15R alpha gene expression through an NF-kappa B site. J Immunol. 2001;166(4):2602-9. (Pubitemid 32173498)
16. Zhao T, Matsuoka M. HBZ and its roles in HTLV-1 oncogenesis. Front Microbiol. 2012;3:247. Importance of HBZ in the pathogenesis of ATLL.
17. Okamoto T, et al. Multi-step carcinogenesis model for adult T-cell leukemia. Jpn J Cancer Res. 1989;80(3):191-5. (Pubitemid 20027205)
18. Moriyama K, et al. Immunodeficiency in preclinical smoldering adult T-cell leukemia. Jpn J Clin Oncol. 1988;18(4):363-9.
19. Gabet AS, et al. High circulating proviral load with oligoclonal expansion of HTLV-1 bearing T cells in HTLV-1 carriers with strongyloidiasis. Oncogene. 2000;19(43):4954-60.
20. Sugata K, et al. HTLV-1 bZIP factor impairs cell-mediated immunity by suppressing production of Th1 cytokines. Blood. 2012;119 (2):434-44.
21. Taylor GP, Matsuoka M. Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene. 2005;24 (39):6047-57.
22. Yamada Y, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001;113(2):375-82.
23. Tsukasaki K, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25(34):5458-64.
24. Lewis JA, Mengheri E, Esteban M. Induction of an antiviral response by interferon requires thymidine kinase. Proc Natl Acad Sci USA. 1983;80(1):26-30.
25. Shibata D, et al. Human T Cell lymphotropic virus type I (HTLV-1)-Associated adult T Cell lymphoma in a patient infected with human immunodeficiency virus type ;1(HIV-1). Ann Intern Med. 1989;111(11):871-5. First description of efficacy of AVT in ATLL. (Pubitemid 20000020)
26. Gill PS, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995;332(26):1744-8. First reports of efficacy in AVT in ATLL patients.
27. Hermine O, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995;332(26):1749-51. First reports of efficacy in AVT in ATLL patients.
28. Matutes E, et al. Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. Br J Haematol. 2001;113(3):779-84.
29. Hermine O, et al. A prospective phase II clinical trial with the use of zidovudine and interferon-Alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J. 2002;3(6):276-82.
30. Bazarbachi A, et al. Meta-Analysis on the use of zidovudine and interferon-Alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28 (27):4177-83. Worldwide analysis of large series of patients confirming of AVT in Leukaemic forms of ATLL.
31. Hodson A, et al. Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia/lymphoma. J Clin Oncol. 2011;29(35):4696-701. Further large series of patients confirming benefit of AVT in ATLL.
32. Ishitsuka K, et al. Interferon-Alpha and zidovudine for relapsed/refractory adult T cell leukemia/lymphoma: case reports of Japanese patients. Int J Hematol. 2010;92(5):762-4.
33. Takasaki Y, et al. Long-Term study of indolent adult T-cell leukemia-lymphoma. Blood. 2010;115(22):4337-43.
34. Goodbourn S, Didcock L, Randall RE. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol. 2000;81(Pt 10):2341-64.
35. Oliere S, et al. HTLV-1 evades type I interferon antiviral signaling by inducing the suppressor of cytokine signaling 1 (SOCS1). PLoS Pathog. 2010;6(11):e1001177.
36. Feng X, Heyden NV, Ratner L. Alpha interferon inhibits human Tcell leukemia virus type 1 assembly by preventing Gag interaction with rafts. J Virol. 2003;77(24):13389-95.
37. Isono T, Ogawa K, Seto A. Antiviral effect of zidovudine in the experimental model of adult T cell leukemia in rabbits. Leuk Res. 1990;14(10):841-7.
38. Taylor GP, et al. Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-Tax cytotoxic T-cell frequency in patients with HTLV-1-Associated myelopathy. J Virol. 1999;73(12):10289-95.
39. Macchi B, et al. Susceptibility of primary HTLV-1 isolates from patients with HTLV-1-Associated myelopathy to reverse transcriptase inhibitors. Viruses. 2011;3(5):469-83.
40. Afonso PV, et al. Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors. Blood. 2010;116(19):3802-8.
41. Datta A, Nicot C. Telomere attrition induces a DNA double-strand break damage signal that reactivates TP53 transcription in HTLV-I leukemic cells. Oncogene. 2008;27(8):1135-41.
42. Datta A, et al. Persistent inhibition of telomerase reprograms adult T-cell leukemia to TP53-dependent senescence. Blood. 2006;108(3):1021-9. Mechanism of AZT in ATLL and requirement for wild type TP53 status. (Pubitemid 44154640)
43. Tawara M, et al. Impact of TP53 aberration on the progression of Adult T-cell Leukemia/Lymphoma. Cancer Lett. 2006;234(2):249-55.
44. Ramos JC, et al. IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma. Blood. 2007;109(7):3060-8. Disease resistance to AVT by recogntion of overexpression of IRF-4. (Pubitemid 46482107)
45. Alizadeh AA, et al. Expression profiles of adult T-cell leukemialymphoma and associations with clinical responses to zidovudine and interferon alpha. Leuk Lymphoma. 2010;51(7):1200-16.
46. Hermine O, et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J. 2004;5(2):130-4. (Pubitemid 38519262)
47. Kchour G, et al. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood. 2009;113(26):6528-32.
48. El Hajj H, et al. Therapy-induced selective loss of leukemiainitiating activity in murine adult T cell leukemia. J Exp Med. 2010;207(13):2785-92.
49. Ishida T, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T cell leukaemia -lymphhoma: a multicenter phase II study. J Clin Oncol. 2012;30:837-42. This paper decribes a phase II study of anti CCR4 antibody in relapsed ATLL patients reporting an overall response rate of 50%.